Small cell lung cancer(SCLC)is an aggressive subtype of neuroendocrine tumor.It is characterized by a rapid doubling time and early development of metastatic disease.Despite being responsive to initial chemotherapy,mo...Small cell lung cancer(SCLC)is an aggressive subtype of neuroendocrine tumor.It is characterized by a rapid doubling time and early development of metastatic disease.Despite being responsive to initial chemotherapy,most of the patients will have relapse of the disease within a few months.The prognosis of SCLC is dismal with a 5-year survival rate of less than 5%.For that reason,management of SCLC has been an active area of research.The utilization of immunotherapy has provided promising results in treatment of SCLC in the front-line setting.Therefore,utilization of immunotherapy and targeted therapy is being studied in the setting of relapsed/refractory disease,and currently,different clinical trials are exploring new drugs and further options.In this review,we will explore the latest updates in management of relapsed/refractory SCLC.展开更多
文摘Small cell lung cancer(SCLC)is an aggressive subtype of neuroendocrine tumor.It is characterized by a rapid doubling time and early development of metastatic disease.Despite being responsive to initial chemotherapy,most of the patients will have relapse of the disease within a few months.The prognosis of SCLC is dismal with a 5-year survival rate of less than 5%.For that reason,management of SCLC has been an active area of research.The utilization of immunotherapy has provided promising results in treatment of SCLC in the front-line setting.Therefore,utilization of immunotherapy and targeted therapy is being studied in the setting of relapsed/refractory disease,and currently,different clinical trials are exploring new drugs and further options.In this review,we will explore the latest updates in management of relapsed/refractory SCLC.
